文献速递白血病

双重靶向MTOR:高危B细胞急性淋巴细胞白血病的新治疗策略

Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia.
PubMed 文献 · Leukemia · 2021-02-02

西班牙裔/拉丁裔儿童高危B细胞急性淋巴细胞白血病(HR B-ALL)发病率高、预后差,其特征为IKZF1单拷贝缺失和PI3K/AKT/mTOR通路激活。本研究发现IKAROS抑制MTOR转录,而致癌性CK2激酶削弱该抑制作用;CK2抑制剂CX-4945增强IKAROS对MTOR的转录抑制,与雷帕霉素直接抑制mTOR蛋白联合,在体外和西班牙裔/拉丁裔儿童HR B-ALL患者来源异种移植模型中显示协同治疗效果。

要点

  • HR B-ALL中IKZF1缺失导致IKAROS对MTOR转录抑制减弱。
  • CK2抑制剂CX-4945增强IKAROS对MTOR的转录抑制。
  • 雷帕霉素联合CX-4945在体外和PDX模型中协同治疗HR B-ALL。

核心结论

  • 双重靶向MTOR(雷帕霉素抑制mTOR蛋白联合CX-4945增强IKAROS介导的MTOR转录抑制)在HR B-ALL中显示协同治疗效果。
  • 该策略有潜力减少西班牙裔/拉丁裔儿童HR B-ALL的健康差异。

研究设计与样本

  • 本研究为实验室研究,包括体外实验和西班牙裔/拉丁裔儿童HR B-ALL患者来源异种移植(PDX)模型。

主要发现

  • IKAROS抑制MTOR转录,而致癌性CK2激酶削弱IKAROS对MTOR的抑制作用。
  • CX-4945增强IKAROS作为MTOR转录抑制因子的活性,降低HR B-ALL中MTOR表达。
  • 雷帕霉素与CX-4945联合在体外和PDX模型中显示协同治疗效果。

临床怎么用

  • 雷帕霉素联合CX-4945的双重靶向MTOR策略可作为HR B-ALL的潜在精准治疗方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Children of Hispanic/Latino ancestry have increased incidence of high-risk B-cell acute lymphoblastic leukemia (HR B-ALL) with poor prognosis. This leukemia is characterized by a single-copy deletion of the IKZF1 (IKAROS) tumor suppressor and increased activation of the PI3K/AKT/mTOR pathway. This identifies mTOR as an attractive therapeutic target in HR B-ALL. Here, we report that IKAROS represses MTOR transcription and IKAROS' ability to repress MTOR in leukemia is impaired by oncogenic CK2 kinase. Treatment with the CK2 inhibitor, CX-4945, enhances IKAROS activity as a repressor of MTOR, resulting in reduced expression of MTOR in HR B-ALL. Thus, we designed a novel therapeutic approach that implements dual targeting of mTOR: direct inhibition of the mTOR protein (with rapamycin), in combination with IKAROS-mediated transcriptional repression of the MTOR gene (using the CK2 inhibitor, CX-4945). Combination treatment with rapamycin and CX-4945 shows synergistic therapeutic effects in vitro and in patient-derived xenografts from Hispanic/Latino children with HR B-ALL. These data suggest that such therapy has the potential to reduce the health disparity in HR B-ALL among Hispanic/Latino children. The dual targeting of oncogene transcription, combined with inhibition of the corresponding oncoprotein provides a paradigm for a novel precision medicine approach for treating hematological malignancies.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Ge Z, Song C, Ding Y, et al. Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia. Leukemia. 2021. PMID: 33531656. doi:10.1038/s41375-021-01132-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。